Clinical outcome measures for research in multiple sclerosis

Area of Science:

• Neurology
• Clinical Trials
• Outcome Measurement

Background:

• Effective multiple sclerosis (MS) therapies necessitate more sensitive clinical outcome measures for research.
• The widely used Kurtzke Expanded Disability Status Scale (EDSS) has limitations in sensitivity, scaling, and components for cognitive and visual function.
• There is a growing need for advanced assessment tools in MS clinical trials.

Purpose of the Study:

• To introduce the Multiple Sclerosis Functional Composite (MSFC) as an improved outcome measure for MS research.
• To highlight the advantages of the MSFC over the EDSS.
• To emphasize the importance of incorporating visual function and health-related quality of life (HRQOL) measures.

Main Methods:

• The MSFC integrates three objective and quantitative tests: the timed 25-ft walk, the nine-hole peg test, and the 3-second paced auditory serial addition test.
• Investigating candidate visual function measures, such as the low-contrast Sloan letter chart, for potential inclusion in the MSFC.
• Developing disease-specific HRQOL measures like the MS Quality of Life Inventory to capture patient-reported outcomes.

Main Results:

• The MSFC provides continuous scoring with a composite Z score, standardized protocols, and demonstrated reliability and validity.
• The MSFC addresses limitations of the EDSS, offering enhanced sensitivity, particularly in active-arm comparison studies.
• Ongoing research aims to integrate visual function and HRQOL measures for a comprehensive assessment.

Conclusions:

• The MSFC represents a significant advancement in outcome measurement for multiple sclerosis research.
• Future MS clinical trials will benefit from the enhanced sensitivity and comprehensive nature of the MSFC.
• Incorporating measures of visual function and HRQOL is crucial for a holistic evaluation of MS impact.